A European committee backed wider Talzenna use with enzalutamide and hormone-blocking treatment for some people with prostate cancer. The European Commission still must make the final decision, but the committee's support favors Pfizer.
A wider use could let Pfizer offer Talzenna to more people with prostate cancer in Europe. The committee's view is not final. The European Commission must still decide whether to change the drug's allowed use.
Follow Pfizer (PFE) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for PFE